Background
Methods
Ethics approval
Patients
Blood parameters
Statistical analysis
Results
Patient characteristics
Parameter | Number (%) |
---|---|
Age, years | |
>65 | 14 (30.4%) |
≤65 | 32 (69.6%) |
Gender | |
Male | 36 (78.3%) |
Female | 10 (21.7%) |
Chemotherapy regimen | |
XELOX | 32 (69.6%) |
FOLFOX | 14 (30.4%) |
Cycles of chemotherapy, median (range) | 3 (1–5) |
Primary tumor site | |
Upper 1/3 | 12 (26.1%) |
Middle 1/3 | 12 (26.1%) |
Low 1/3 | 22 (47.8%) |
Clinical responsea | |
Yes | 21 (45.7%) |
No | 25 (54.3%) |
Clinical benefitb | |
Yes | 43 (93.5%) |
No | 3 (6.5%) |
Types of surgery | |
Total | 28 (60.9%) |
Subtotal | 18 (39.1%) |
Radicality | |
R0 | 37 (80.4%) |
R1 | 0 |
R2 | 9 (19.6%) |
Combined resection | |
No | 45 (97.8%) |
Yes | 1 (2.2%) |
Differentiation | |
Differentiatedc | 15 (32.6%) |
Poorly differentiatedd | 31 (67.4%) |
Clinical TNM classificatione | |
T stage | |
T3 | 40 (87%) |
T4 | 6 (13%) |
N stage | |
N1 | 14 (30.4%) |
N2 | 32 (69.6%) |
N3 | 0 |
TNM stage | |
III | 40 (87%) |
IV | 6 (13%) |
Pathological TNM classificatione | |
y T stagef | |
T0 | 2 (4.3%) |
T1 | 1 (2.2%) |
T2 | 6 (13%) |
T3 | 28 (60.9%) |
T4 | 9 (19.6%) |
y N stagef | |
N0 | 8 (17.4%) |
N1 | 19 (41.3%) |
N2 | 13 (28.3%) |
N3 | 6 (13%) |
y TNM stagef | |
Tis | 1 (2.2%) |
I | 3 (6.5%) |
II | 8 (17.4%) |
III | 23 (50%) |
IV | 11 (23.9%) |
Blood parameters
Prognostic variables for PFS and OS
Factors | Number | Univariate analysisa, P value | Multivariate analysisb, | |
---|---|---|---|---|
HR (95% CI) | P value | |||
Radicality | ||||
R0 | 37 | 0.163 (0.063 to 0.421) | <0.001 | |
R1 | ||||
R2 | 9 | <0.001 | 1 | |
Differentiation | ||||
Differentiatedc | 15 | |||
Poorly differentiatedd | 31 | 0.039 | ||
Pre-chemotherapy blood parameters | ||||
Neutrophils, cells/mm3 | ||||
≤4000 | 24 | |||
>4000 | 22 | 0.065 | ||
NLR | ||||
≤2.5 | 22 | 1 | ||
>2.5 | 24 | 0.012 | 2.329 (1.069 to 5.073) | 0.033 |
Pre-operative blood parameters e | ||||
Neutrophils, cells/mm3 | ||||
≤4000 | 34 | |||
>4000 | 12 | 0.049 | ||
NLR | ||||
≤2.5 | 26 | 1 | ||
>2.5 | 20 | 0.019 | 2.347 (1.128 to 4.881) | 0.022 |
Factors | Number | Univariate analysisa, P value | Multivariate analysisb | |
---|---|---|---|---|
HR (95% CI) | P value | |||
Radicality | ||||
R0 | 37 | 0.127 (0.050 to 0.320) | <0.001 | |
R1 | ||||
R2 | 9 | <0.001 | 1 | |
Differentiation | ||||
Differentiatedc | 15 | |||
Poorly differentiatedd | 31 | 0.061 | ||
Pre-operative blood parameters | ||||
Neutrophils, cells/mm3 | ||||
≤4000 | 34 | |||
>4000 | 12 | 0.037 | ||
NLR | ||||
≤2.5 | 26 | |||
>2.5 | 20 | 0.082 |
Normalization of pre-chemotherapy NLR and correlation with PFS and OS
NLR changed by chemotherapya | Number | PFS | OS | ||||
---|---|---|---|---|---|---|---|
Median survival, months | P value | Median survival, months | P value | ||||
NLR >2.5 | → | NLR >2.5 | 13 | 10 | 16 | ||
NLR ≤2.5 | → | NLR ≤2.5 | 15 | 49 | <0.001 | 42 | 0.015 |
NLR >2.5 | → | NLR ≤2.5 | 11 | 35 | 60 | ||
NLR ≤2.5 | → | NLR ≤2.5 | 15 | 49 | 0.648 | 42 | 0.869 |
NLR >2.5 | → | NLR ≤2.5 | 11 | 35 | 60 | ||
NLR >2.5 | → | NLR >2.5 | 13 | 10 | 0.003 | 16 | 0.042 |